We know that, Linaclotide (BELOW STRUCTURE) is an experimental peptide agonist of guanylate cyclase 2C that is undergoing clinical trials for use in treating abdominal pain in patients with irritable bowel syndrome (IBS) accompanied by constipation. The drug was developed by Ironwood Pharmaceuticals, based in Cambridge, Massachusetts.
Now researchers lead by, Dr. Anthony J. Lembo, an associate professor of medicine at Harvard
Medical School and director of the GI Motility Center at Beth Israel
Deaconess Medical Center in Boston, have come up with interesting claim that "people who received the drug had improvement in symptoms, and the treatment was generally well-tolerated".
Researchers conclude that, linaclotide significantly reduced bowel and abdominal symptoms in
patients with chronic constipation (2 trials). Additional studies are needed to
evaluate the potential long-term risks and benefits of linaclotide in
chronic constipation...
Ref : http://www.nejm.org/doi/full/10.1056/NEJMoa1010863
